Skip to content

A Clinical Study on the Efficacy and Mechanism of Huolong Can Combined with Acupuncture in Treating Lumbar Disc Herniation with Secondary Sciatica

A Clinical Study on the Efficacy and Mechanism of Huolong Can Combined with Acupuncture in Treating Lumbar Disc Herniation with Secondary Sciatica

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001219
Enrollment
Unknown
Registered
2026-05-14
Start date
2025-09-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar disc herniation resulting in sciatica.

Interventions

Observation group: Fire Dragon Can combined with acupuncture:Acupuncture, fire cupping
Control group: Acupuncture group:Acupuncture

Sponsors

Fuyang City Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for sciatica secondary to lumbar disc herniation; (2) Aged 30-60 years, gender, with mild to moderate pain or functional impairment in the non-acute phase (more than 2 weeks since onset), and no severe comorbidities that would make cooperation difficult; (3) Has not taken painkillers or neurotrophic medications recently, and has not undergone systematic treatment; (4) Voluntarily participates in this study, is able to cooperate with examinations and treatments, can understand and complete thequestionnaires and scales, and is willing to sign the informed consent form. All four criteria must be met simultaneously for inclusion in the trial.

Exclusion criteria

Exclusion criteria: (1) Severe progressive neurological symptoms (e.g., cauda equina syndrome and progressive muscle weakness); (2) History of lumbar spine trauma or surgery; (3) Severe osteoporosis or bone tumors; (4) Abnormalities in heart, liver, or kidney function; hematological diseases; or mental disorders; (5) Impaired skin integrity, allergic symptoms, or bleeding disorders; (6) Contact allergies or sensitivity to moxibustion smoke; (7) Pregnancy or breastfeeding in women; (8) Currently participating in other clinical trials. Subjects who meet any of the above criteria will be excluded.

Design outcomes

Primary

MeasureTime frame
NRS;

Secondary

MeasureTime frame
CRP;IL-6;JOA;ODI;

Countries

China

Contacts

Public ContactZhang Yu

Fuyang City Traditional Chinese Medicine Hospital

1225374254@qq.com15956881705

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026